Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel ribbon-type nuclear factor of activated T cells decoy oligodeoxynucleotides preclude airways hyperreactivity and Th2 cytokine expression in experimental asthma.
Nakamura Y, Nagashima H, Akiyama M, Sato A, Miyamoto T, Sasaki N, Nitanai H, Kowata K, Nakadate T, Kobayashi H, Uesugi N, Sugai T, Kakiuchi T, Inoue H, Yamauchi K. Nakamura Y, et al. Among authors: nagashima h. Int Arch Allergy Immunol. 2011;155(2):129-40. doi: 10.1159/000319826. Epub 2010 Dec 22. Int Arch Allergy Immunol. 2011. PMID: 21196757
Multiple Scedosporium apiospermum abscesses in a woman survivor of a tsunami in northeastern Japan: a case report.
Nakamura Y, Utsumi Y, Suzuki N, Nakajima Y, Murata O, Sasaki N, Nitanai H, Nagashima H, Miyamoto S, Yaegashi J, Hatakeyama T, Shibano Y, Yarita K, Kamei K, Nakadate T, Endo S, Terayama Y, Yamauchi K. Nakamura Y, et al. Among authors: nagashima h. J Med Case Rep. 2011 Oct 25;5:526. doi: 10.1186/1752-1947-5-526. J Med Case Rep. 2011. PMID: 22027347 Free PMC article.
Scedosporium aurantiacum brain abscess after near-drowning in a survivor of a tsunami in Japan.
Nakamura Y, Suzuki N, Nakajima Y, Utsumi Y, Murata O, Nagashima H, Saito H, Sasaki N, Fujimura I, Ogino Y, Kato K, Terayama Y, Miyamoto S, Yarita K, Kamei K, Nakadate T, Endo S, Shibuya K, Yamauchi K. Nakamura Y, et al. Among authors: nagashima h. Respir Investig. 2013 Dec;51(4):207-11. doi: 10.1016/j.resinv.2013.07.001. Epub 2013 Aug 20. Respir Investig. 2013. PMID: 24238227 Review.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Saito H, et al. Among authors: nagashima h. Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8. Lancet Oncol. 2019. PMID: 30975627 Clinical Trial.
Elemental and mutational analysis of lung tissue in lung adenocarcinoma patients.
Chiba R, Morikawa N, Sera K, Ishida K, Nagashima H, Shigeeda W, Deguchi H, Tomoyasu M, Hosokawa T, Saito H, Sugai T, Yamauchi K, Maemondo M. Chiba R, et al. Among authors: nagashima h. Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S224-S234. doi: 10.21037/tlcr.2019.08.18. Transl Lung Cancer Res. 2019. PMID: 31857947 Free PMC article.
Analysis of bevacizumab treatments and metastatic sites of lung cancer.
Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M. Sato H, et al. Among authors: nagashima h. Cancer Treat Res Commun. 2021;26:100290. doi: 10.1016/j.ctarc.2020.100290. Epub 2020 Dec 26. Cancer Treat Res Commun. 2021. PMID: 33373900 Free article.
Relationship between Trace Element in Tumor and Prognosis in Lung Cancer Patients.
Saikawa H, Nagashima H, Cho K, Chiba R, Sera K, Shigeeda W, Tomoyasu M, Deguchi H, Takahashi F, Saito H, Sugai T, Maemondo M. Saikawa H, et al. Among authors: nagashima h. Medicina (Kaunas). 2021 Feb 26;57(3):209. doi: 10.3390/medicina57030209. Medicina (Kaunas). 2021. PMID: 33652756 Free PMC article.
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Kawashima Y, et al. Among authors: nagashima h. Lancet Respir Med. 2022 Jan;10(1):72-82. doi: 10.1016/S2213-2600(21)00166-1. Epub 2021 Aug 26. Lancet Respir Med. 2022. PMID: 34454653 Clinical Trial.
1,202 results